Precision medicine represents a paradigm shift in healthcare, aiming to tailor medical interventions to individual characteristics, allowing for more personalized and effective treatments. The role of precision medicine in developing healthcare and treatment is not just about individualized care; it signifies a paradigm shift towards a more proactive, informed, and patient-centric healthcare system (1). As our understanding of genetics deepens and technology continues to evolve, precision medicine will undoubtedly play an increasingly pivotal role in shaping the future of healthcare, offering a level of precision and effectiveness that was once deemed the stuff of futuristic visions. In this new era, healthcare is not just about treating diseases; it’s about understanding and optimizing the unique genetic tapestry of each individual for a healthier, more resilient tomorrow (2). Wearable and implantable biosensors have emerged as key enablers in this transformative journey, offering continuous, real-time monitoring of physiological parameters. On the other front, wearable biosensors have ushered in a new era of healthcare by providing a continuous stream of data about an individual’s physiological status. These devices, ranging from smartwatches and fitness trackers to more specialized medical-grade sensors, can monitor parameters such as heart rate, blood pressure, glucose levels, and even more complex metrics like ECG patterns. Wearable biosensors offer a real-time, comprehensive view of a person’s health, enabling early detection of anomalies and facilitating proactive healthcare interventions (3).

Wearable biosensors, integrated into clothing or accessories, provide a non-intrusive means of collecting a wealth of data, including vital signs, activity levels, and even biochemical markers. These devices empower individuals to actively participate in their healthcare, fostering a proactive approach to well-being. Moreover, the seamless integration of data from wearables into electronic health records facilitates a comprehensive understanding of a patient’s health status (4).

Implantable biosensors, on the other hand, delve deeper into the intricacies of the human body, offering unprecedented access to internal physiological processes. These miniaturized marvels are designed to monitor specific biomarkers, providing clinicians with intricate insights into disease progression and treatment response. The potential for early detection of anomalies and swift intervention holds promise for preventing diseases before they manifest clinically (5).

The synergy between wearable and implantable biosensors contributes to a holistic approach to precision medicine. Continuous data streams from wearables serve as a foundation for baseline health, while implantable offer focused, in-depth information on specific parameters. Integrating this wealth of data through advanced analytics and artificial intelligence not only refines diagnostics but also enhances predictive modeling for treatment outcomes (6). The amalgamation of real-time, personalized data from these devices holds the promise of transforming healthcare from reactive to proactive, offering a future where medical interventions are precisely tailored to individual needs, optimizing outcomes, and improving the overall quality of life. This review explores the pivotal role of these biosensors in advancing precision medicine.

In the relentless pursuit of improving healthcare outcomes, precision medicine has emerged as a revolutionary paradigm, challenging the conventional one-size-fits-all approach. Unlike traditional medicine, which often employs generalized treatments, precision medicine tailor’s healthcare strategies to the unique genetic, environmental, and lifestyle characteristics of each individual. This bespoke approach not only transforms the landscape of diagnosis and treatment but holds the potential to redefine the entire healthcare experience (7, 8). Armed with genetic insights, healthcare providers can identify potential health risks long before symptoms manifest. This early detection empowers a proactive approach to healthcare, where interventions can be implemented to prevent the onset of diseases or manage them at their earliest stages (9). This knowledge allows healthcare professionals to prescribe drugs that are not only effective but also tailored to each patient, minimizing the trial-and-error process often associated with medication regimens. Precision medicine contributes to a deeper understanding of diseases at the molecular level. This knowledge not only aids in more accurate diagnoses but also fuels ongoing research, leading to the development of innovative therapies that target the specific mechanisms driving diseases (10).

In the ever-evolving landscape of healthcare, the convergence of precision medicine and wearable biosensors has emerged as a groundbreaking frontier, promising personalized and real-time insights into an individual’s health. Precision medicine, which tailors medical care to the unique characteristics of each patient, and wearable biosensors, compact devices that continuously monitor physiological parameters, are joining forces to revolutionize how we approach diagnosis, treatment, and overall healthcare management (11).

When precision medicine and wearable biosensors intersect, the synergy created is nothing short of transformative. Imagine a scenario where a patient’s genetic predisposition to a particular condition is combined with real-time data from wearable biosensors, allowing healthcare providers to predict, prevent, or manage diseases with unprecedented accuracy (12, 13). By integrating genetic data with continuous monitoring, healthcare professionals can identify early signs of diseases or health risks, enabling preventive measures to be implemented before symptoms manifest. Personalized treatment plans, informed by both genetic insights and real-time physiological data, ensure that interventions are tailored to an individual’s unique profile. This targeted approach enhances treatment efficacy and reduces the risk of adverse reactions (14, 15). Wearable biosensors enable remote patient monitoring, allowing healthcare providers to track a patient’s health in real-time without the need for frequent clinic visits (16). This is particularly beneficial for individuals with chronic conditions or those recovering from surgery. The wealth of data generated by wearable biosensors, when analyzed in conjunction with genetic information, contributes to a deeper understanding of the factors influencing health outcomes (17). This data-driven approach facilitates ongoing research, leading to continuous improvements in precision medicine (Figure 1). Here, we have compiled a summary of recent advances in the development of wearable biosensors for monitoring health and disease-related symptoms with the aim of ameliorating various health-threatening diseases in different organs of the body.

In 2003, Cardionet Inc. developed the first mobile telemetry system, which recorded ECG and uploaded ambulatory data via cellular connections. It also contained algorithms for automatically transmitting and detecting asymptomatic and symptomatic events (18). Over the past five to 10 years, advanced technologies have emerged, targeting consumers and businesses. The most commonly used accelerometer is found in phones, wrists, and textiles. Accelerometers detect acceleration by measuring sensor displacement or mechanical stress applied in the system. They can also be used for heart sound monitoring by evaluating auditory vibrations, detecting conditions based on intensity, frequency, quality, and duration. However, noise from motion artifacts is a major limitation (19).

Ballistocardiogram (BCG) is an accelerometer-based technique that detects cardiac motion, allowing for the detection of heart rate, blood pressure, and myocardial contractility (20). Seismocardiogram (SDG) uses a chest wall sensor to detect chest wall vibrations, gathering information on heart rate, blood pressure, and cardiac output (21, 22). Photoplethymography (PPG) detects variations in blood pressure within microvasculature. It can be used with smartphones or accessory devices to measure pulsatile activity, detecting heart rate and heart rhythm, but measurements can be affected by body movement, temperature, hair, skin color, and tattoos (23, 24). Electrode-based technology is increasingly used in healthcare monitoring, recording single-lead electrocardiograph (ECG) using two vectors. These techniques can detect heart rate and rhythm, as well as ischemia, but these readings are subject to noise and artifacts and are limited to a single lead analysis. There are already several commercialized wearable ECG devices in the market including smartwatches, such as those offered by companies like Apple, Fitbit, and Samsung, often include ECG functionality as a feature (Figures 2A,B). These devices can measure heart rate and record ECG waveforms, providing users with insights into their cardiac health (31). Smart wristbands and patches are also available in the market, offering ECG monitoring capabilities. These devices are designed to be worn on the wrist or attached to the body, allowing continuous ECG monitoring, and other wearable devices, such as intelligent three-lead electrocardiograph monitors, have been developed to provide ECG monitoring with feedback functions for warning potential heart attacks (32). Patches with embedded electrodes have the ability to wirelessly transmit and record ambulatory ECG data for longer periods of time than a standard Holter. They offer details on the heart rate, pauses, high grade atrioventricular block, counts of isolated supraventricular and ventricular ectopic beats, and runs of supraventricular and ventricular tachycardia (Table 1). The Zio Patch (iRhythm Technologies, Inc. San Francisco, United States), a leadless electrocardiographic monitoring device, has been evaluated in 26,751 consecutive patients for its effectiveness in detecting arrhythmias. The findings could have significant implications for device selection, monitoring duration, and care pathways for arrhythmia evaluation and AF surveillance (33). ePatch is a lightweight, body-worn sensor that records and stores heart rhythm data, which can be downloaded and evaluated by cardiac monitoring professionals (34). A novel study evaluated the performance of a medical wearable, Everion^® (Biovotion AG, Switzerland), using passive PPG technology for AF detection in patients with paroxysmal or persistent AF during inpatient conditions (Figure 2C). Reliable and continuous monitoring of AF by employing a deep neural network demonstrated a 95.2% sensitivity and a 92.5% sensitivity (28). A prospective clinical trial compared the performance of a 14-day continuous electrocardiogram patch (EZYPRO^®, Sigknow Biomedical Co., Ltd., Taipei, Taiwan) for detecting arrhythmias compared to conventional 24 h monitoring. The patch was associated with higher detection rates in patients with SVT, irregular SVT without P wave, AF/AFL, and critical arrhythmias (35). The KoMaWo configuration (SmartMedics, Poland), a new variation of ECG electrode positioning, has been tested on 15 patients with ST segment deviations due to coronary artery disease, offering extended monitoring and increased diagnostic accuracy for cardiac arrhythmias, making them a viable alternative to traditional cardiac monitoring methods (36).

Numerous devices are available for health monitoring, including the Apple Watch (Apple Inc., Cupertino, CA, United States), which incorporates accelerometer and PPG-based technologies for heart rate tracking and arrhythmia detection. Smartphone accessories like KardiaMobile (Mountainview, CA), Preventicus (Preventicus^®, Jena, Germany), and Pulse-Smart (Medicore Co., Ltd. in South Korea) use PPG technology to detect arrhythmias and heart rate using touchpad electrodes (37). The Cardiio Rhythm smartphone PPG application (Cardiio Inc., Cambridge, United States) has provided an accurate and reliable means to detect AF in patients at risk of developing AF, potentially enabling population-based screening for AF (38). Other accurate blood pressure monitoring devices include a small sensor attached to a smartphone, a pressure sensor worn continuously over the wrist, and a system that incorporates both SCG and BCG technology through a chest patch and wrist watch (39). A vest with built-in sensors, electrode connections, and an optical probe clipped on the ear can monitor heart rate, oxygen saturation, and activity levels, as well as dynamic changes in cardiopulmonary function during activity (40). The majority of consumer electronics are heart rate or activity monitors, which can reduce the risk of cardiovascular disease. Wearing pedometers increases daily activity levels, decreases BMI, and lowers blood pressure (41). Mobile apps and wearable devices have been shown to lead to greater weight loss in obese patients (42). In addition, there are several other examples of intermittent atrial fibrillation detection tools used in clinical and research settings including MyDiagnostick (Applied Biomedical Systems BV, Maastricht, Netherlands), Zenicor-ECG, and FibriCheck (Qompium, Hasselt, Belgium). The MyDiagnostick and Zenicor-ECG are commercially available single-lead electrocardiograph devices for AF detection with high sensitivity and specificity (Figure A) (43, 44). FibriCheck is an FDA-cleared photoplethysmography-based smartphone application for heart rate measurement and AF identification (25).

Wearable devices are widely used for disease screening, particularly in detecting arrhythmias. The Apple Heart Study found that the Apple Watch can detect asymptomatic atrial fibrillation (Afib) using PPG technology (45). These devices can also help in risk stratification patients with known cardiovascular diseases by tracking vitals and activity levels. These devices significantly impact decision-making and help patients make informed decisions such as Galaxy Watch Active 2, Simband, and AliveCor’s KardiaBand (Figure 2D) (26, 27). In addition to disease prevention and screening, these technologies can also help in change management. For instance, a patient experienced ST depressions on their Apple Watch, which can alert them to arrhythmias and ischemia (46). Electrode technology has shown promise in detecting ischemia, as demonstrated in a study involving 200 patients with suspected STEMI symptoms. The study used smartphone-derived ECGs, Livecore, attached to an iPod Touch, and found a good correlation between the two. Overall, ischemia detection using Livecore can be relatively reliable (47). Another study involving 45 patients with chronic heart failure found that seismocardiography chest patch technology can differentiate between compensated and decompensated heart failure states. Although not widely used, these technologies have great potential in providing better care for patients (48).

Research on using wearable devices for activity tracking has been used in studies to determine the relationship between post-operative activity and length of stay after major surgeries, including cardiac surgery. It can also serve as an endpoint in drug trials, such as nitrates for heart failure patients to improve activity (49, 50). A meta-analysis of digital health interventions, including telemedicine, web-based monitoring, email messaging, mobile phone tracking, text messaging, and monitoring sensors, found that overall outcomes were better in patients who underwent digital health interventions compared to those receiving usual care. Out of the 1,200 patients in the digital health interventions group, about 100 developed events, while 160 in the usual care group developed events (51). Digital health interventions appear to have more effect on secondary prevention of cardiovascular diseases and heart failure patients compared to primary prevention. A pilot study showed that the ReDS vest may reduce heart failure readmissions. Fifty patients were admitted for decompensated heart failure and were instructed to wear the vest for 90 days. After 90 days, the readmission rates were compared. The vest significantly reduced heart failure readmissions compared to pre-and post-wear periods. Although not routinely used, the vest could significantly reduce the disease burden and mortality of cardiovascular diseases (52). With the emergence of the Internet of Things (IoT) era, the development of self-powered wearable medical sensors using flexible electronic devices is on-demand. A self-powered wearable electrocardiography (ECG) system was demonstrated, powered by a wearable thermoelectric generator (w-TEG) using body heat. Parametric studies were conducted on the PHS, and the w-TEG structure was optimized. The output power density was over 38 μW/cm for the first 10 min and 13 μW/cm for 22 h (Figures 2E,F) (29, 30).

By providing valuable insights into the brain’s activities and overall health, wearable biosensors have the potential to enhance diagnostics, improve treatment outcomes, and enable personalized care for individuals with neurological conditions (53). In this section, we will explore the significant role of wearable biosensors in neurological care and their potential to transform the way we understand and manage neurological disorders.

The brain sends command prompts through the spinal cord, but the connection between the brain and the body can be broken due to physical injury or degenerative disease. The brain computer interface (BCI) can function as a bridge to bypass this broken connection. Existing BCI technology can be categorized into invasive and non-invasive (Figure 3A) (57). The Utah Array, the current industry standard, is a square computer chip with spikes that can read electrical signals from the cortex region of the brain. This process allows a person with a brain implant to control electronic devices with their brain, such as robotic limbs or computers. However, this method is limited to medical research environments (58). The next generation of BCI technology, led by startups like Synchron, Blackrock Neurotech, and Neuralink, could potentially become life-changing medical technology for paralyzed individuals in the near future. Blackrock’s device is implanted directly into the brain (Figure 3C), while Synchron’s is implanted into blood vessels in the brain (Figure 3B). Blackrock Neurotech’s BCI the NeuroPort, uses a series of tiny brain chips, called NeuroPort arrays which consist of 96 densely packed electrodes to record and stimulate neurons with high precision from virtually anywhere on the brain surface. Multiple arrays can be placed in one person, creating brain-computer interfaces and neuroprosthetics that can control objects and repair senses. The signals are transmitted wirelessly to an outside device like a wheelchair or cursor, giving people control over their environment (55). Blackrock has also partnered with the University of Pittsburgh’s rehab neural engineering labs to create the first portable brain computer interface, allowing patients to participate in research trials (69). Neuralink, a founding company, plans to implant electrodes directly into people’s brains, potentially providing a cure for neurological disorders like spinal cord injury, seizures, paralysis, and depression.

The Neuralink device, resembling a small coin, uses a robotic sewing machine to insert fine and flexible electrode wires into the outer cortex layer. This device could be used to operate robots, cure paralysis, treat mental illness, stream music, and extend hearing range beyond normal frequencies. The Neuralink device resembles the Utah array and could potentially cure neurological disorders (56). In mid-2021, ClearPoint Neuro and Blackrock Neurotech collaborated to develop an automated surgical solution for placing brain computer interface devices in patients with neurological disorders like paralysis, ALS, and hearing loss (Figure 3D) (67). Additionally, ClearPoint has partnered with Higgs boson health to launch a digital patient-facing application using the Manage My Surgery platform, focusing on drug delivery to the spine and brain, as well as BCI technology (Figure 3E) (70). BrainGate researchers have demonstrated the first human use of a high bandwidth wireless brain computer interface with an external wireless transmitter, allowing users to operate external devices like computers and robotic arms with their minds. Initial clinical research demonstrated the system’s ability to intuitively control advanced prosthetic limbs and robotic devices, providing paralysis patients with simple control, powerful assistive movement, and communication devices. The ultimate goal is for people to take the device home and use it for daily activities. This research aims to improve independence, mobility, and safety for blind people (Figure 3F) (59).

Electrocorticography (ECoG) is a non-invasive procedure that uses electrodes placed directly on the brain, allowing for better and more precise signals. It has a higher spatial resolution of approximately 4 square millimeters, making analysis more complex. ECoG grids consist of small disk-like electrodes placed epidurally or subdurally, and the distance between electrodes can vary depending on the region of interest (71). Epilepsy patients with ECoG are often observed for several days or weeks to identify epileptogenic zones, providing a unique opportunity to study electric activity at high spatial and temporal resolution (72). Recent advances allow for long-term or chronic placement of ECoG sensors, enabling the development of ECoG-based brain computer interfaces and closed-loop approaches (73). ECoG can also be used to control prosthetics, recording movement planning signals from the motor cortex and translating them to actual movement of an artificial arm or hand (74). EEG or EMG can be used to control robots and smart devices, such as prosthetics. The Walk Again Project has demonstrated the use of EEG-controlled exosuits to help people walk again, using motor-imagery patterns as triggers to move the robot’s legs (Figure 3M) (65). Mind-controlled wheelchairs provide basic directional control using motor imagery, p300 signals, or population encoding (75). CTRL labs developed a wristband that accurately maps finger actuation and hand positioning using electromyographic signals and accelerometer data (76). Several companies are working on developing novel EEG based BCI electrodes interpreting neural activity using artificial intelligence, allowing users to control objects with their minds (77, 78). In a more recent study, a digital bridge between the brain and spinal cord was developed based on the brain-spine interface (BSI) implant to restore communication between the brain and the spinal cord, allowing individuals with chronic tetraplegia to walk naturally in community (79).

Traditional BCIs have often utilized rigid electrodes, which, while effective in capturing neural signals, have faced challenges in terms of long-term use and patient comfort. The transition to flexible electrodes marks a significant advancement, addressing these concerns and opening up new possibilities for interfacing with the brain, highlighting significant benefits including enhanced comfort and biocompatibility, improved signal quality, versatility in placement, and long-term stability. Several promising reports are published on the applications of flexible BCI systems in health-related fields such as neuroprosthetics, neurorehabilitation, and cognitive enhancement (Figures 3H–K) (60–63).

A cutting-edge development in the realm of BCI systems is the emergence of portable, wireless, weakly-invasive BCIs that not only push the frontiers of performance but also enhance user convenience and accessibility. The convergence of portability, wireless connectivity, and weakly-invasive design in BCIs heralds a new era of human-computer interaction. As these systems evolve, they promise to redefine our relationship with technology, offering not only enhanced capabilities but also a glimpse into the profound possibilities of the human mind (Figure 2A) (54, 66, 80).

In 2013, Nicolelis and a team of researchers developed the first brain-to-brain interface (BTBI), enabling lab rodents to share sensorimeter information and work together for rewards (81). The BraiNet project connected the brains of three primates, allowing them to move an arm over a target in digital 3D space (82). BCI applications focus on total levels of brain activity and frequency bands, and are used for meditation, focus, and sleep enhancement. Neurofeedback technology changes cues based on brain indicators, such as wakefullness, and is used for meditation, sleep, focus, and seizure monitoring (83). A team of researchers developed a way for disabled artists to create art using a brain computer interface (84). The Neuracle NeuSenW is a fast, small, lightweight, compact, flexible, and wearable system that can transmit up to 64 channels of high-quality EEG wirelessly at up to 16 kilohertz per channel. This system is robust for ambulatory use in naturalistic environments and allows high-accuracy synchronization across multiple devices (85). BIOSEMI, Cognionics, ANT Neuro, G. Tec, Brain Products, and EMOTIV are among the most common EEG-based electrodes mobile systems used to study the neural control of human locomotion (86). A speech neuroprosthetic device was developed by researchers at the University of California San Francisco, which can decode full words and sentences from brain signals of participants who have been unable to speak due to a trauma-induced stroke. The device is placed over motor areas associated with speech and can decipher between words in a predetermined set and construct sentences. Data was collected from an electrocorticography array, semi-invasive, paper-thin grids of flat, circular electrodes placed underneath the skull but on top of the brain (87).

Parkinson’s disease (PD) is the second most prevalent neurodegenerative disease, affecting millions worldwide. Diagnosing PD can be challenging due to its diverse symptoms and similarities with other illnesses (88). Wearable brain implants have gained attention as valuable tools for managing PD, providing continuous monitoring and objective measurements of motor symptoms. Sensor-equipped wearable devices have shown significant potential in improving early diagnosis and monitoring of PD (89). One notable application of wearable brain implants in PD is the development of an Internet of Things (IoT) platform, pioneered by the Michael J. Fox Foundation for Parkinson’s Disease Research and Intel Corporation (90). Exopulse researchers have developed a suit called Mollii, which uses neuromuscular electrical stimulation to correct muscle tremors caused by degenerative brain disorders. This technology can effectively treat conditions like Parkinson’s, Cerebral Palsy, Spasticity, Multiple Sclerosis, and Chronic Pain (91). Deep brain stimulation (DBS) is FDA-approved for Parkinson’s disease and epilepsy, and has a humanitarian device exemption for dystonia and obsessive-compulsive disorder. There are three FDA-approved DBS therapy devices available: Medtronic, Abot SJM, and Boston Scientific. DBS has been used to treat chronic pain and depression, OCD, as well as other psychiatric disorders like anxiety and PTSD. DBS is like a pacemaker for the brain, improving quality of life by correcting abnormal brain rhythms (Figure 3P) (68, 92). Researchers are developing medical devices and AI-driven solutions to improve life for people with Parkinson’s. One such device is the CUE1 non-invasive wearable device, which uses pulsed cueing and focused vibrotactile stimulation to reduce symptoms of slowness and stiffness, resulting in improved movement (93).

The next generation of neural implants are being developed at Lawrence Livermore National Laboratory (LLNL) to deepen the exploration of the brain. In collaboration with the National Institute of Health (NIH), University of California San Francisco (UCSF), and other research institutes, engineers are developing brain-based healthcare devices using thin-film micro-electrocorticography surface arrays. These devices can record more information about an individual’s brain state, making treatment more informative and effective (94, 95). This technology is also paving the way for next-generation neural prostheses or implantable devices that could improve the ability of those with disabilities to see, speak, or hear (96, 97). Researchers have developed ultraflexible electrode arrays that can record thousands of neurons in live animals’ brains for months. These recordings enhance decoding accuracy during optogenetic stimulation and enable the detection of strongly coupled neuron pairs, enabling the study of large-scale neural circuits and patterns of information flow (Figure 3L) (64). UC Berkeley engineers have developed a wireless, implantable sensor that records electrical signals in nerves, providing real-time data for quadriplegic individuals to use prosthetic limbs. The neural dust used in the device records electrical activity in brain nerve cells, which can be analyzed to guide prosthetics (Figure 3N) (66). Engineers are working on creating a lifetime neural dust implant, which could potentially guide prosthetics and improve the quality of life for individuals with disabilities (98). Wearable biosensors are crucial in neurorehabilitation by enabling continuous monitoring and objective assessment of motor functions and movement patterns. These sensors promote adherence to therapy, monitor progress, and facilitate early intervention, contributing to neuroplasticity and functional recovery. Integrating wearable biosensors in neurological care fosters research and advancements, enabling population-scale studies to identify patterns, risk factors, and potential interventions for neurological disorders (99).

Ocular wearable contact lenses are a promising technology for non-invasive point-of-care testing and monitoring of various ocular diseases. These lenses make direct contact with ocular surfaces and are integrated with electronic devices and biosensors to detect biomarkers within the eye. These devices offer continuous and long-term measurement capabilities, enabling patients to manage their symptoms effectively and conveniently (100). The eye, being a complex sensory organ, contains abundant information that can be harnessed for wearable healthcare platforms. Ocular wearable devices, such as smart contact lenses or glasses, are designed to integrate biosensors that can measure various parameters related to ocular health. These biosensors can detect and monitor biomarkers in tears, enabling the assessment of physiological and pathological conditions (101).

Tears provide a direct connection to the blood and exhibit close correlations between tear and blood biomarker concentrations, allowing for the analysis of tear fluid as a non-invasive means of evaluating ocular health. Ocular wearable biosensors can detect specific biomolecules, such as proteins, enzymes, and metabolites, in tears, providing insights into ocular disease states. The analysis of tears offers potential for diagnosing ocular diseases, including conditions such as dry eye syndrome, glaucoma, and ocular inflammation (102).

Smart contact lenses offer noninvasive real-time detection of the human body for biomedical information. However, accurate measurement of physiological signals in tears is challenging. A self-powered multiplexed sensor based on organic electrochemical transistors (OSCs) was demonstrated, allowing semilog-linear response to glucose and calcium ions in tear fluids (103). Another interesting study represented a fluorescent scleral lens sensor was also developed based on a handheld ophthalmic readout device and a smartphone camera for quantitative measurements of physiological levels of pH, Na⁺, K⁺, Ca²⁺, Mg²⁺, and Zn²⁺ ions in point-of-care settings (104). A soft contact-lens biosensor (SCL-biosensor) was fabricated and tested for non-invasive biomonitoring of tear fluids, showing excellent correlation between output current and glucose concentration (105). A human pilot trial demonstrated that a novel soft, smart contact lens based on a graphene field-effect transistor sensor had a suitable sensitivity for real-time cortisol concentration detection in tears using a smartphone with a low detection limit (106).

Recently, exosomes have gained attention as a valuable source of disease biomarkers. A poly (2-hydroxyethyl methacrylate) contact lens with antibody-conjugated signaling microchambers (ACSM-PCL) has been developed to detect tear exosomes that can detect exosomes in various solutions, including regular buffer, cell culture media, and human tears. The ACSM-PCL is expected to be a next-generation smart contact lens for cancer pre-screening and supportive diagnosis (Figure 4A) (107).

Several biochemical or biophysical sensors have been integrated into contact lenses for detecting single biomarkers in tear fluids, eyeball movement, and mechanical deformation. Wearable contact lenses monitor physiological parameters, but previous sensors only detect one analyte at a time. A multifunctional sensor was developed on an actual ocular contact lens using graphene and metal nanowires for measuring glucose levels in tears and intraocular pressure, evaluated in in-vivo and in-vitro tests using rabbit and bovine eyeballs. This system enables continuous, noninvasive monitoring of physiological conditions and biomarkers related to ocular and other diseases (114).

Microfluidics technology has been used to create contact lens sensors that can identify substances in tears, such as glucose, pH, nitrite, proteins, and ascorbic acid, through multiple sensing channels. A study demonstrated the integration of paper microfluidics in laser-inscribed contact lenses for multiplexed detection of clinically relevant analytes, such as hydrogen ions, proteins, glucose, nitrites, and L-ascorbic acid. This device has potential for medical diagnosis, disease screening, and monitoring of ocular infections, uveitis, diabetes, keratopathies, and oxidative stress (Figure 4B) (108). Microfluidic contact lenses have also been developed as wearable platforms for in situ tear pH, glucose, protein, and nitrite ions sensing. A microchannel was inscribed using CO₂ laser ablation, and biosensors were embedded within microcavities that responded within 15 s, yielding high sensitivities in detection of pH, glucose, proteins, and nitrites. These contact lens sensing platforms could provide on-eye tears screening and monitor ocular health in clinics and point-of-care settings (115).

Evaporation, humidity, tears, and rain can affect eye concentration levels uncorrelated to blood concentration variation. Measurement in the tear film is insufficient for accurate electrochemical measurements and useful diagnostic conclusions. Electrochemical smart contact lenses (ESCL) have been developed to monitor chemical markers found in the tear film (116). A promising work presents a next-generation with four microelectrode arrays in lens quadrants, enabling real-time spatiotemporal sensing of concentration variation. The fast-switching chronoamperometric technique enables real-time electrochemical measurement of concentration flow, paving the way for clinical use (117).

Advancements in miniaturization, sensor technology, and wireless communication have led to the development of ocular wearable devices and biosensors. These devices allow for continuous monitoring of ocular health parameters, enabling early detection of ocular abnormalities and timely interventions. One significant application of contact lens sensors is the measurement of intraocular pressure (IOP), which is crucial for diagnosing and managing glaucoma (Figure 4F) (112, 118). Wearable contact lenses offer the potential for at-home monitoring without the need for patients to stay awake during measurements. Researchers have introduced integrated theranostic smart contact lens, which uses a gold hollow nanowire-based sensor, flexible drug delivery system, wireless power, communication, and an application-specific integrated circuit chip. This lens successfully monitors and controls pressure levels in glaucoma-induced rabbits, making it a promising personal healthcare platform for glaucoma and other ocular diseases (Figure 3D) (110). Several studies have been focused on developing functional contact lenses for regular tracking IOP because monitoring intraocular pressure (IOP) is crucial in the early diagnosis of glaucoma to prevent or slow down vision loss (119, 120). For example, a smart soft contact lenses (SSCL) for continuous 24 h monitoring of intraocular pressure (IOP) during sleep was introduced. These lenses retain intrinsic lens features like power, biocompatibility, softness, transparency, wettability, and oxygen transmissibility. They offer overnight wearability, ergonomic curvature fitting, mechanical and chemical durability, and disposable after multiple uses, making them crucial for transforming SSCL into glaucoma care (121).

Contact lens sensors have also been explored for the detection of other biomarkers and ocular pathologies. For example, the integration of biosensors with contact lenses enables the measurement of glucose levels in tear fluid, offering potential applications in diabetes management (122). These lenses also have the potential to detect various ocular conditions and optimize pharmaceutical treatments (123). Diabetic patients with poorly managed blood sugar levels are at risk of developing glaucoma, cataracts, and different degrees of diabetic retinopathy. Measuring tear glucose levels can be implemented as an alternative to traditional strips for noninvasive monitoring of blood glucose levels in diabetes mellitus diagnosis and treatment. A nanoparticle embedded contact lens (NECL) was developed as a biocompatible biosensor for noninvasive glucose monitoring, combining glucose oxidase and cerium oxide (III) and detecting changes in the reflection spectrum with glucose concentration (124). Furthermore, a noninvasive smart wireless far red/near-infrared (NIR) light emitting contact lens has been developed for repeated treatment of diabetic retinopathy. The lens uses a far red/NIR LED, an integrated circuit chip, wireless power, and communication systems, demonstrating its safety and feasibility in biomedical photonic applications. In vitro characterization confirmed that repeated wearing reduced retinal vascular hyper-permeability in rabbits (Figure 4G) (113). In recent years, intraocular islet transplantation has been introduced as a new diabetes treatment procedure that requires close monitoring of eye and islet graft function. A soft, smart contact lens has been developed to monitor intraocular pressure, detecting changes in pressure and transmitting real-time values wirelessly (Figure 4C) (109).

Revolutionize ophthalmology by providing valuable insights into ocular health, facilitating early diagnosis, and enabling personalized treatment strategies. The non-invasive nature of tear analysis and the convenience and accessibility of ocular wearables hold promise for improved ocular disease management and patient care. Advanced flexible contact lenses can dynamically monitor vital ocular indicators, spot abnormalities, and provide biofeedback guidance for real-time diagnosis and rehabilitation tracking of chronic eye diseases (125). A flexible multifunctional lens, based on inorganic γ-Fe₂O₃@NiO magnetic oxide nanosheets, has been designed with the capability to monitor glucose levels, eyeball movement, and intraocular pressure, offering personalized and efficient health management (114). Researchers have developed 2D biocompatible, flexible plasmonic contact lenses for red-green color blindness, which are low-cost, simple, and based on soft nano-lithography. These lenses offer new insights for color blindness correction applications due to their biocompatibility, low cost, stability, and simplicity (126). A pilot trial of a smart contact lens and skin-attachable therapeutic device for wireless monitoring and therapy of chronic ocular surface inflammation (OSI) has been conducted. The smart contact lens measures matrix metalloproteinase-9 concentration in tears, while the therapeutic device is a stretchable heat patch (127). Both devices can be integrated with smartphones for wireless communication, enabling instant diagnosis and automated hyperthermia treatments. In vivo tests confirm their biocompatibility and reliability as a noninvasive, mobile health care solution.

The materials used in contact lens sensors play a crucial role in their performance. Biocompatible polymers, such as hydrogel silicones, are commonly used for constructing the lenses, ensuring comfort and safety during prolonged wear (128). Lenses are integrated with biosensors that can measure specific analytes in tear fluid, ocular surface temperature, intraocular pressure (IOP), pH value, and other relevant parameters. To address the keratoconus, myopia, and corneal deformation, a biocompatible dye, RB, was conjugated to hyaluronic acid (HA) to enhance corneal permeability. This smart contact lens have potential on-demand HA-RB conjugate delivery, potentially enabling biophotonic myopia vision correction (Figure 4E) (111). In another attempt, an LC resonator strain sensor in a contact lens composed of a stretchable inductance coil and a chip capacitor has been developed for real-time IOP monitoring. It is ultra-soft, comfortable, safe, and stable, with linear and stable responses. It has been calibrated on silicone rubber eyeballs and has a higher sensitivity than mainstream lens sensors, making it a promising approach for 24 h continuous IOP monitoring in clinics (119).

As a multifunctional platform, contact lenses can simultaneously serve as wearable sensors for continuous monitoring ocular diseases and as a drug delivery system for treating these diseases. Soft contact lenses have the potential to deliver a variety of drugs, including antibiotics, antifungals, anti-inflammatory agents, and even glaucoma medications. The drug delivery system is achieved through the incorporation of the drug into the lens material or using the lens as a reservoir to release the drug over time. Microfluidic and electrochemical contact lenses offer the potential for personalized medicine and individualized drug regimens, allowing healthcare professionals to customize the drug release profile based on the specific needs of each patient. This personalized approach enhances treatment outcomes while minimizing the risk of drug resistance and optimizing therapeutic efficacy (129).

In the dynamic landscape of healthcare, non-invasive glucose monitoring biosensors have emerged as beacons of progress, introducing a paradigm shift in the management of diabetes. Imagine a world where individuals no longer need to endure the inconvenience of routine finger-pricking, and instead, gain real-time insights into their glucose levels effortlessly. In this narrative of innovation, non-invasive glucose monitoring biosensors in tears, sweat, saliva, and interstitial fluid stand as pillars of progress, embodying the spirit of a future where healthcare is both personalized and seamlessly integrated into our daily lives. The amalgamation of data from tears, sweat, saliva, and interstitial fluid opens avenues for comprehensive health analytics. Researchers can harness this wealth of information to not only refine diabetes management strategies but also contribute to a broader understanding of the intricate interplay between glucose regulation and overall health. Non-invasive glucose monitoring biosensors have been meticulously designed to analyze specific biomarkers in saliva, offering a painless and convenient alternative to traditional blood-based methods. The richness of information within saliva provides a comprehensive view of glucose dynamics, enabling a more nuanced and personalized approach to diabetes management (Figures 5I, E–G) (134–136). Furthermore, interstitial fluid, the fluid that surrounds cells in our bodies, has become another focal point for these biosensors. By tapping into this reservoir just beneath the skin, biosensors can glean precise glucose readings without the need for invasive procedures. This approach not only enhances user comfort but also facilitates continuous monitoring, providing a continuous stream of data crucial for understanding glucose fluctuations throughout the day (Figures 5I, A,B) (130, 131). With advancements in biosensor technology, sweat has become a dynamic canvas for monitoring glucose levels. Wearable devices equipped with these biosensors now offer athletes, fitness enthusiasts, and individuals at large an unobtrusive means of tracking glucose fluctuations during physical activities, providing a valuable tool for optimizing performance and health (148). Tears are also used as a promising fluid for non-invasive glucose monitoring using wearable biosensors, providing a gentle and hassle-free means of assessing glucose levels that seamlessly integrating glucose monitoring into daily life without the need for intrusive measures (Figures 5I, C,D) (132, 133).

In the last 20 years, continuous glucose monitor (CGM) has significantly transformed the way diabetes is managed. CGM systems use a tiny sensor to test the interstitial fluid between body cells, checking glucose levels every 5 min. The information is then sent wirelessly to a reader, which displays the levels. Most CGM systems have three parts: a disposable sensor, a transmitter, and a monitor, typically smaller than a cell phone. This technology enables people with diabetes and healthcare professionals to monitor glucose readings on a receiving device or app, allowing for more accurate treatment decisions. Real-time CGM systems may reduce the need for regular finger pricks for individuals with diabetes (149). Sensor-based automatic insulin delivery devices have entered the market since the introduction of the first automatic insulin delivery device in 2006. These include Dexcom, Medtronic, Freestyle Libre, Eversense, Omnipod, T:slim X2, Tandem Mobi, Waveform cascade CGM, Bigfoot diabetes management system, Lily connected smart pen, and Novopen 6 smart pen. The Omnipod 5 pump device consists of a Bluetooth-enabled pod with insulin, a Dexcom G6 sensor that communicates directly with the pod, and a personal diabetes manager device that sends glucose values commands to the pod (Figure 5II, C) (138). The Dexcome G7 is a smaller, longer-weighted device that combines the sensor and transmitter in the same device (Figure 5II, A) (137). The Medtronic MiniMed 780G is an advanced hybrid closed loop system (AHCL) using a new generation 4 sensor, requiring only one calibration on the first day of wear (Figure 5II, A) (140). The Freestyle Libre 3 device is a thin real-time sensor that transmits data to the phone every minute and displays it on the mobile app (Figure 5II, D) (139). The Waveform cascade device is a 15-day CGM with a rechargeable transmitter approved in Europe in 2019, and communicates with a mobile app via Bluetooth with high accuracy (Figure 5II, I) (144). The Bigfoot Unity diabetes management system integrates a smart pen cap with the Freestyle Libre 3 to transmit insulin dosing information between the pen and mobile app (Figure 5II, J) (145). There are two versions of the pen cap, one for long-acting and the other for rapid-acting insulins. Lily’s disposable pen transmits data from the pen to the mobile app on the dosing and has a Tempo smart button. NovoPen 6 is another smart CGM pen made by Nova Nordis (Figure 5II, L) (147). The mylife YpsoPump is a small and light smart CGM sensor that uses an orbital infusion set, saving crimping and other problems (Figure 5II, K) (146). The EOpatch is a tubeless insulin patch pump developed by EOflow company, undergoing FDA approval. It is a small pod that stores insulin attached to the skin and can be used for 3.5 days or replaced on fixed days of the week for regular use. The closed-loop system mimics the human pancreas, automatically delivering the exact dose of insulin needed (Figure 5II, H) (143).

Over the past 15 years, scientists have been working on the artificial pancreas project, which aims to incorporate the essential function of the human pancreas. The bionic pancreas requires a smartphone as the command and control center housing, a software program that determines actions based on data from the glucometer, and a glucometer capable of continuous monitoring of blood glucose levels (150). A study by Russell et al. (151) compared the effectiveness of a Dexcom G4 platinum continuous monitor glucometer to an insulin pump, which accurately assesses blood glucose levels through a subcutaneously placed probe. The third component is a pump with separate reservoirs of insulin and glucagon, which can inject hormone subcutaneously into the user using a signal from the cellphone program. Patients with type 1 diabetes rely on various insulin delivery methods, such as insulin pens, insulin pumps, or hybrid closed-loop systems, which require substantial use interaction. The bionic pancreas is highly automated and requires only the patient’s body weight to start therapy. An impressive study, sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, demonstrated that automated glucose control with a bionic pancreas can significantly reduce the glycated hemoglobin level in children and adults with type 1 diabetes (Figure 5II, F) (141). The iLet bionic pancreas is the first fully automated insulin pump, requiring only weight and input from daily meals to learn insulin requirements. A study of over 400 participants found that after 3 months, the iLet insulin pump reduced HbA1c by 0.5%, increased time and range by 2.6 h, and did not increase hypoglycemia. The wearable device can be adjusted to function as an insulin-only, glucagon-only, or bi-hormonal artificial pancreas using both insulin and glucagon (Figure 5II, G) (142). Several successful trial studies have evaluated artificial pancreas for use by type 2 diabetes patients (152, 153). Cambridge scientists developed an artificial pancreas for type 2 diabetes patients using an algorithm developed at the University of Cambridge. The CamAPS FX device combines an off-the-shelf glucose monitor and insulin pump with an app that predicts insulin requirements. The device is fully closed loop, requiring no kidney dialysis, unlike the artificial pancreas used for type 1 diabetes. The Nature Medicine team reported the first trial of this fully closed-loop system for type 2 diabetes patients, recruiting 26 patients and dividing them into two groups. After 8 weeks, the average glucose levels fell from 12.6 mmol/L to 9.2 mmol/L while using the artificial pancreas. The app also reduced levels of glycated hemoglobin (HbA1c), which helps clinicians understand an individual’s average blood sugar levels over weeks or months (154).

House monitors like Apple Watch and Fitbit primarily track health signs during physical activities, but they lack molecular information. This presents a significant challenge for developing wearable devices that track chemical biomarkers continuously and non-invasively. Electrochemical sensors offer high sensitivity, selectivity, speed, miniaturization, low costs, low energy consumption, and ease of use. These sensors offer numerous advantages, including continuous chemical information, better adherence to health, nutrition, and wellness assessment, self-care, preventive medicine, distance diagnosis, lower healthcare costs, and improved people’s lives (155). However, these sensors face challenges such as stability, accuracy, safety, compliance with body movement, energy demands, big data, and data security (156). There is a wide range of wearable electrochemical sensors for real-time continuous non-invasive monitoring of various substances, including metabolites, electrolytes, drugs, hormones, vitamins, cytokines, stress markers, and disease markers (157, 158). These sensors can be flexible and printable electrodes incorporated into clothing or attached directly to the body. Screen-printing technology, used for single-use disposable glucose biosensor strips, is an attractive route for fabricating wearable electrochemical sensors. Scientists worldwide are now using large-scale low-cost sensor fabrication to create a wide array of wearable sensor patterns on flexible substrates or textiles (159). However, the lack of stretchability of electrochemical devices hinders their wearable applications, and it is crucial to bridge the gap between softness of biology and rigid electrochemistry by developing flexible and stretchable printed electrochemical devices (160).

Epidermal monitoring offers non-invasive ways to assess a wearer’s physiological state through lab-on-skin devices like E-skin tattoo biosensors (161), printable textile-based sensors (162), and minimally-invasive microneedle sensors (163). These devices integrate tattoo-transfer and thick-film fabrication processes to continuously monitor sweat chemistry (Figure 6H) (171, 172). The first epidermal enzyme electrode was designed to monitor sweat lactate concentration (Figure 6I) (172), and other flexible printable temporary-transferred tattoos functionalized with the enzymes were used for glucose and alcohol concentration in sweat or interstitial fluid (ISF) for fitness and performance (180). Researchers have developed a temporary skin-worn electrochemical biosensor for non-invasive glucose monitoring, combining reverse iontophoretic extraction of interstitial glucose with an enzyme-based amperometric biosensor. This device’s data is comparable to traditional blood glucose measurements (Figure 5B) (165). Researchers are now able to monitor simultaneously both sweat alcohol and glucose ISF by designing a single flexible wearable biosensor platform, enabling on-demand sampling and monitoring of both biofluids (Figure 6C) (166). These studies are moving towards personalized nutrition, providing timely nutrition feedback and guidance for supporting dietary behavior change. The ultimate goal towards personalized nutrition is to get comprehensive information about monitoring nutrition like metabolite, electrolyte, calcium, sodium, and potassium continuously at the molecular level not only in sweat but in tears, saliva, and ISF (181). Recently, researchers have developed wearable chemical-electrophysiological hybrid sensing systems that integrate multiple sensing modalities into a single platform. These systems record vital signs and chemical information simultaneously, such as blood pressure chemical sensing (BPCM) and electrochemical sensors for sweat and ISF biomarkers like lactate and glucose. The multimodal sensing without crosstalk, skin comfortability, and mechanical resiliency make it possible for performance during exercising and daily activities (Figures 6K,L) (174).

Fingertips are one of the sweatiest spots on the body and offer opportunity of sensing and energy applications without the need for sweat stimulation. Scientists have developed a touch-based technique for fingertips sweat bioelectronics, utilizing passive perspiration from the fingers without the need for sweat stimulation. This technique allows for rapid sensing of cortisol concentration in natural fingertip sweat, allowing label-free measurement from the decreased current response of the PB redox probe embedded in the polymeric network (182). The fingertip touch-based sensor was used in Parkinson’s patients to track L-dopa pharmacokinetic profile following oral tablet administration (183). A dual disposable fingertip touch-based sensing device was developed, integrating neighboring ketone and glucose enzyme electrodes on a single-strip substrate for simultaneous detection of ketone and glucose (184). Different epidermal sensing devices were designed in the form of fashion accessories like sunglasses, gloves, and bandages. The eyeglasses-based wireless sensor platform consists of potentiometric sensors for electrolytes and amperometric sensors for metabolites, allowing real-time monitoring of metabolites or electrolytes in tears and sweat (Figure 6I) (173).

Tattoo-based sensors have long mechanical strain capabilities, but recent studies focus on sweat microfluidic analysis for efficient sampling, flow, and removal. A skin-mounted microfluidic device, developed at UC San Diego University, is now commercialized by Innovosens for non-invasive, simultaneous multiparametric measurement of sweat metabolites for sport and fitness (Figure 6G) (170). Printable textile-based sensors with super mechanical stress-enduring features have been developed, embedding sensors directly on the elastic waist of underwear. Examples include a highly stretchable and printable textile-based potentiometric sensor array, which combines stretchable components like polyurethane, Ecoflex, and stretch-enduring inks for simultaneous multi-ion sweat analysis (Figure 6P) (178). Bandage-based biosensors are also well-performance wearable electrochemical sensors for monitoring wound healing and detecting the presence of tyrosinase (TYR) enzyme cancer biomarker in the presence of its immobilized catechol substrate for melanoma cancer screening and diagnosis (Figure 6F) (169). The researchers are also working towards a lab-under-the-skin microneedle sensor arrays that can physically disrupt the outer layer of the skin in a minimally-invasive, painless manner (185). The interstitial fluid (ISF) microenvironment is closely related to blood, offering an attractive minimally-invasive skin compartment. A multiplexed microneedle sensor array platform has been developed for simultaneous transdermal monitoring of key health ISF biomarkers, such as glucose, alcohol, insulin, cortisol, lactate, and ketone (186). A self-powered glucose biosensor is already commercialized by Biolink company, which uses enzyme-modified carbon paste (CPE)-containing microneedle arrays with 9 hollow microneedles loaded with CPE (Figure 6N) (176). A microneedle-based sensor for Parkinson’s management is designed for continuous monitoring of L-dopa and precise dose regulation using different microneedles on the same patch (187). A minimally-invasive microneedle sensor was developed by integrating a microneedle patch with a 1.5 centimeter diameter for continuous monitoring of multiple chemical markers in subcutaneous tissue (Figure 6M) (175). In a very recent study, the reliability of the sweat-sensing system in noninvasively monitoring important biomarkers in the human body was confirmed by developing a wireless, battery-free, flexible, self-pumping sweat-sensing system for the long-term monitoring of changes in the status of levodopa and vitamin C in sweat, which can be useful in diagnosis, medication, and nutritional assessment (Figure 6A) (164). Three microneedle skin-offs companies, Biolink, Aquilx, and Nutramics, are focusing on drug monitoring in diseases like diabetes and Parkinson’s.

Meeting anatomically compliant power sources is crucial for progressing in wearable biomedical devices, which require miniaturization and flexibility to enable wearer activity. To have a complete control of the energy demand, scientists are developing flexible energy harvesting and storage systems, such as epidermal biofuel cells, tattoo-based batteries, supercapacitors, textile-based energy microgrids, and hybrid multi-modal energy systems (Figure 6D) (167, 188). Epidermal biofuel cells are highly stretchable and designed to scavenge bioenergy from wearers, like sweat. A team of researchers at UC San Diego developed a flexible, stretchable powerful “island-bridge” biofuel cell to increase power density (Figure 5E) (168). They also combined energy harvesting with energy storage on textiles, creating a hybrid energy system with biofuel cells on one side and supercapacitors on the other (Figure 6O) (177). High-performance flexible batteries are being developed, such as stretchable Zn-Ag₂O batteries with a high reversible capacity density well suited for realizing chip-scale energy storage for integrated electronic systems. The ultimate goal is to combine complementary and synergistic energy harvester and storage modules to develop multi-modular wearable grid systems (189). Another example of a new self-sustainable wearable multi-modular bioenergy microgrid system that meet the demands of energy supply is a multi-module, textile-based energy-powering system with applications powered by complementary and synergistic energy harvesters and commensurate energy storage modules (Figure 6Q) (179). They recently combined all functionalities with an electrochromic display in the form of a unique patch design with high stretchability and changing color ability to visualize the sweat lactate concentration, which can be life-changing for cardiac care patients, organ transplant recipients, and people with diabetes. These non-invasive sensors could be used for fine-tuning electrolytes in athletes, peak performance, and military pilots in high-pressure jobs (190).

Researchers have tested a bioartificial kidney prototype, aiming to free kidney disease patients from dialysis machines and transplant waiting lists. The prototype, combining hemofilter and bioreactor components, was implanted for preclinical evaluation. The device powered by blood pressure without blood thinning or immunosuppressant drugs. The artificial kidney could offer complete mobility and better physiological outcomes than dialysis. The team plans to upscale the technology for more preclinical testing (191, 192).

Scientists have developed a multiplex COVID-19 diagnosis platform called SARS-CoV-2 RapidPlex, based on low-cost graphene-based laser-engraved technology. This system monitors virus antigen, antibodies, and inflammatory biomarkers in saliva and blood in less than 10 min. The system has good selectivity and accuracy compared to gold standard ELISA, distinguishing patients from healthy individuals and identifying influential biomarkers like CRP for monitoring COVID infection severity (193).

A study demonstrates that non-invasive magnets can effectively treat glioblastoma, a challenging brain cancer, with a 31% reduction in tumor volume in just over one month. The device, consisting of three rotating magnets called oncoscillators, is compact and simple for at-home treatment. The researchers created an oncomagnetic device, which covered the entire brain with minimal side effects. The tumor shrinks rapidly, with a 10% reduction after 3 days and a 30% reduction at 30 days. This is a significant step forward in cancer treatment, and it is hoped that treating cancer will soon be as easy as putting on a hat (194).

Envoy Medical’s Acclaim^® cochlear implant is an investigational device aimed at improving hearing for adults with moderate to profound sensorineural hearing loss. If approved by the FDA, it would be the first cochlear implant without external components, ensuring no loss or damage. The implant uses novel sensor technology from Envoy Medical’s Esteem osseointegrated active middle ear implant (AMEI), which was FDA-approved in 2010 (195).

Advanced endoscopes with imaging and therapy capabilities offer advantages but lack spatial resolution for diagnosing and treating small cancers. A multifunctional endoscope-based interventional system combines transparent bioelectronics with theranostic nanoparticles, enabling optical fluorescence-based mapping, electrical impedance and pH sensing, contact/temperature monitoring, radio frequency ablation, and localized photo/chemotherapy. This technology is useful for accurate detection, delineation, and targeted therapy of colon cancer, treating chronic inflammatory bowel diseases, and enhancing tumor detection accuracy (196).

Researchers have developed Pillsense, a swallowable device that detects gastrointestinal bleeding using a fluorescence detector. The world’s smallest floor imager, it uses an LED, lens, optical filter, and excitation filter. This innovative solution could prevent gastrointestinal bleeding in pre-symptomatic individuals without displaying symptoms (197).

There is a significant opportunity in the field of biometric sensors, which offer various modalities, form factors, and insights. Self-powered capabilities can be configured for some of these technologies, but further advancements are needed in sensing mechanisms. Examples include injectable biometric sensors for photoplethysmography, accelerometry, and thermometry (198), battery-free wireless ultrasonic sensors like endoleak sensing in aortic valves (199), and cardiac stem cells patched on the heart powered by ultrasound (200). Transdermal and breath biomarker sensing can detect body conditions like metabolic states or COVID-19 infection (201). Startups like NEXT system, ClearSense, Everactive, Dermisense, VitaFlo, Onda Vision, and Olftech are actively pursuing technology development. Future opportunities include new energy harvesting modes, non-invasive sensing modalities like heat flux sensors, blood pressure sensors, artificial intelligence, and machine learning. Additionally, reconfigurable sensor systems can be used to change the sampling rate or sensing target based on context.

While the integration of precision medicine and wearable biosensors holds immense promise, several challenges must be addressed. These include issues related to data privacy, the need for standardized data formats, and the importance of educating both healthcare providers and the general public about the potential benefits and limitations of these technologies. The integration of biosensors into everyday life presents challenges, including the need for wearable devices to be comfortable, unobtrusive, and fashionably acceptable, and implantables to navigate biocompatibility and long-term stability. Accuracy and reliability of biosensor data are crucial for clinical utility, and bridging gaps between medical, engineering, and data science disciplines is essential. Ethical concerns regarding privacy, consent, and data ownership are crucial for the widespread acceptance and ethical deployment of biosensors in precision medicine.

Future biosensors may leverage advancements in sensing technologies, such as nanoscale sensors and innovative biomaterials, to enhance the specificity and sensitivity of biosensors. Integrated health platforms that combine data from wearable and implantable biosensors with electronic health records could provide healthcare professionals with a comprehensive view of a patient’s health, facilitating more informed and personalized treatment strategies.

Predictive analytics and artificial intelligence are key to extracting meaningful insights from biosensor data, with machine learning algorithms aiding in identifying patterns, predicting disease trajectories, and optimizing treatment plans. As technology evolves, there is a growing potential to empower individuals to actively participate in their healthcare, fostering health literacy and self-management.

In conclusion, while challenges persist, the future prospects of wearable and implantable biosensors in precision medicine are promising. Addressing current obstacles through collaborative efforts and embracing technological advancements could pave the way for a healthcare landscape where personalized interventions based on real-time, accurate data become the standard rather than the exception.

EG: Writing – original draft. ZN: Writing – review & editing. H-PD: Conceptualization, Writing – review & editing. HR: Validation, Visualization, Investigation, Writing – review & editing. ZA: Resources, Conceptualization, Writing – review & editing.